A Phase 3 interventional study of Tadalafil 5 mg and Placebo tablet in Benign Prostatic Hyperplasia (BPH), sponsored by Eli Lilly and Company. Completed at 44 sites in 10 countries. Open to male participants aged 45 Years and older. Per ClinicalTrials.gov, last updated 2012-03-12.
Sponsored by Eli Lilly and Company · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 26 studies testing tadalafil in Prostatic Hyperplasia — 2 open to participants now, 2 under way, none of them phase 3. Tadalafil · Prostatic Hyperplasia.
Among the 26 studies testing tadalafil in Prostatic Hyperplasia, this one is the 7th largest by enrollment, is one of 5 that started in 2009, is one of 10 in phase 3, and was the 10th registered.
828 studies on the registry are indexed under Prostatic Hyperplasia; 179 are open to participants now.
Browse Prostatic Hyperplasia studies →2 of the 26 studies testing tadalafil in Prostatic Hyperplasia are open now, in 1 country. Recruiting first, the newest first:
Beni-Suef University · Sites in Egypt
Ages 50+ · Men only
Assiut University
Men only
By country, each count listing its studies:
Tadalafil: first FDA approval 2003 (CIALIS), first EMA approval 2002. What it is approved for, and how studies give it, is on its page →
Of the 102 Prostatic Hyperplasia studies recruiting now, 70 (69%) set no upper age limit and 4 (4%) stop at 75 or younger; 7 take children under 18; 7 take healthy volunteers.
This study: 45 Years and older · male · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
26 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 5 · Phase 2 5 · Phase 3 11 · Phase 4 6
First in 2004; this study’s year is marked. 5 started in 2009.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 511 is above the median of 92 across 627 interventional studies indexed under Prostatic Hyperplasia.
Median enrollment 258 across the 26 interventional studies. Of the 23 that completed or were terminated, 15 (65%) have results posted.
This tab as a report to print or save as PDF → With an account.
20 of 26 have an industry lead sponsor. The 10 most frequent:
Eli Lilly and Company is the lead sponsor of 2,108 studies on the registry; 153 are open to participants now.
Of its 537 completed or terminated interventional studies of FDA-regulated products, 358 (67%) have results posted.
17 studies in Prostatic Hyperplasia by Eli Lilly and Company: none open now, none under way, none of them phase 3. Of 17 finished, 16 (94%) have results posted.
Among the 17 studies in Prostatic Hyperplasia by Eli Lilly and Company, this one is the 7th largest by enrollment, is one of 5 that started in 2009, is one of 9 in phase 3, and was the 10th registered.
Eli Lilly and Company’s Prostatic Hyperplasia studies by the year they started, since 2004.
1 of the studies testing tadalafil in Prostatic Hyperplasia that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07654413Beni-Suef UniversityTamsulosin With or Without Tadalafil for Trial Without Catheter After Acute Urinary Retention Due to Benign Prostatic Hyperplasia | 2027-11 |
Add it to your calendar (.ics) → With an account.
Among the 26 studies testing tadalafil in Prostatic Hyperplasia, from their registry updates:
Nothing recorded among them since 2026-09-25.
Among Eli Lilly and Company’s 17 in Prostatic Hyperplasia:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
The purpose of this study is to determine whether an experimental drug known as tadalafil given once daily can reduce the symptoms associated with Benign Prostatic Hyperplasia (straining, urinary frequency, feeling like your bladder is still full etc.)
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Placebo tablet with tamsulosin dose orally (po) once daily (QD) and placebo capsule with tadalafil dose po QD for 12 weeks
Drug: Placebo tablet · Drug: Placebo capsule
Tadalafil 5 mg tablet po QD and placebo capsule po QD for 12 weeks
Drug: Tadalafil 5 mg
Tamsulosin 0.4 mg capsule po QD and placebo tablet po QD for 12 weeks
Drug: Tamsulosin
Tadalafil 5 mg po QD for 12 weeks
Also known as: Cialis, LY450190
Placebo tablet po QD for 12 weeks
Tamsulosin 0.4 mg po QD for 12 weeks
Placebo capsule po QD for 12 weeks
Change From Baseline in Total International Prostate Symptom Score (IPSS) at 12 Weeks
The IPSS Total Score was obtained by combining the scores of the responses to Component Questions 1-7. Each question was scored from 0-5 for an IPSS range of 0-35 points; higher numerical scores from the IPSS questionnaire represented greater severity of symptoms. Least Squares (LS) Mean of change from baseline to endpoint (Week 12 or last post-baseline value carried forward) was from an analysis of covariance (ANCOVA) and adjusted for treatment group, region, centered-baseline covariate, centered-baseline-by-treatment interaction, and treatment-by-region interaction.
Time frame: Baseline, 12 weeks
Change From Baseline in Total International Prostate Symptom Score (IPSS) at 4 Weeks
The IPSS Total Score was obtained by combining the scores of the responses to Component Questions 1-7. Each question was scored from 0-5 for an IPSS range of 0-35 points; higher numerical scores from the IPSS questionnaire represented greater severity of symptoms. Least Squares (LS) Mean of change from baseline to endpoint (Week 4 or last post-baseline value carried forward) was from an analysis of covariance (ANCOVA) and adjusted for treatment group, region, centered-baseline covariate, centered-baseline-by-treatment interaction, and treatment-by-region interaction.
Time frame: Baseline, 4 weeks
Change From Baseline in International Prostate Symptom Score (IPSS) Storage (Irritative) Subscore at 12 Weeks
IPSS storage (irritative) subscore was the sum of Component Questions 2, 4 and 7 of the IPSS questionnaire. Scores ranged from 0 (no irritative symptoms) to 5 (frequent irritative symptoms); therefore, the 3 questions of the irritative subscore ranged from 0 to 15. Least Squares (LS) Mean of change from baseline to endpoint (Week 12 or last post-baseline value carried forward) was from an analysis of covariance (ANCOVA) and adjusted for treatment group, region, centered-baseline covariate, centered-baseline-by-treatment interaction, and treatment-by-region interaction.
Time frame: Baseline, 12 weeks
Change From Baseline in International Prostate Symptom Score (IPSS) Voiding (Obstructive) Subscore at 12 Weeks.
IPSS voiding (obstructive) subscore was the sum of Component Questions 1, 3, 5 and 6 of the IPSS questionnaire. Scores ranged from 0 (no obstructive symptoms)-5 (frequent obstructive symptoms); therefore, the 4 questions of the obstructive score ranged from 0-20. Least Squares (LS) Mean of change from baseline to endpoint (Week 12 or last post-baseline value carried forward) was from an analysis of covariance (ANCOVA) and adjusted for treatment group, region, centered-baseline covariate, centered-baseline-by-treatment interaction, and treatment-by-region interaction.
Time frame: Baseline, 12 weeks
Change From Baseline in International Prostate Symptom Score (IPSS) Nocturia Question at 12 Weeks
The IPSS nocturia question (Component Question 7) measured nocturia (need to urinate at night) over the past 4 weeks. Scores ranged from 0 (no episodes of nocturia)-5 (5 or more episodes of nocturia). Least Squares (LS) Mean of change from baseline to endpoint (Week 12 or last post-baseline value carried forward) was from an analysis of covariance (ANCOVA) and adjusted for treatment group, region, centered-baseline covariate, centered-baseline-by-treatment interaction, and treatment-by-region interaction.
Time frame: Baseline, 12 weeks
Change From Baseline in International Prostate Symptom Score (IPSS) Quality of Life (QoL) Index at 12 Weeks
IPSS QoL assessed QoL by urinary symptoms, with scores ranging from 0 (delighted)-6 (terrible). Least Squares (LS) Mean of change from baseline to endpoint (Week 12 or last post-baseline value carried forward) was from an analysis of covariance (ANCOVA) and adjusted for treatment group, region, centered-baseline covariate, centered-baseline-by-treatment interaction, and treatment-by-region interaction.
Time frame: Baseline, 12 weeks
Change From Baseline in Modified International Prostate Symptom Score (mIPSS) at 1 Week
The mIPSS Total Score covered a time period of 1 week and was obtained by combining scores of responses to Component Questions 1-7. Each question was scored from 0-5 for an mIPSS range of 0-35 points; higher numerical scores represented greater severity of symptoms. Least Squares (LS) Mean of change from baseline to endpoint (Week 1 or last post-baseline value carried forward) was from an analysis of covariance (ANCOVA) and adjusted for treatment group, region, centered-baseline covariate, centered-baseline-by-treatment interaction, and treatment-by-region interaction.
Time frame: Baseline, 1 week
Change From Baseline in Benign Prostatic Hyperplasia Impact Index (BII) at 4 Weeks
BII was a 4-item, self-administered questionnaire evaluating impact of urinary problems on overall health and activity. Total scores ranged from 0-13; higher scores represented increased perceived impact of BPH-lower urinary tract symptoms (LUTS) on overall health. Least Squares (LS) Mean of change from baseline to endpoint (Week 4 or last post-baseline value carried forward) was from an analysis of covariance (ANCOVA) and adjusted for treatment group, region, centered-baseline covariate, centered-baseline-by-treatment interaction, and treatment-by-region interaction.
Time frame: Baseline, 4 weeks
Change From Baseline in Benign Prostatic Hyperplasia Impact Index (BII) at 12 Weeks
BII was a 4-item, self-administered questionnaire evaluating impact of urinary problems on overall health and activity. Total scores ranged from 0-13; higher scores represented increased perceived impact of BPH-lower urinary tract symptoms (LUTS) on overall health. Least Squares (LS) Mean of change from baseline to endpoint (Week 12 or last post-baseline value carried forward) was from an analysis of covariance (ANCOVA) and adjusted for treatment group, region, centered-baseline covariate, centered-baseline-by-treatment interaction, and treatment-by-region interaction.
Time frame: Baseline, 12 weeks
Patient Global Impression of Improvement (PGI-I) at 12 Weeks
The PGI-I was a participant-rated instrument that measured the improvement or worsening of the participant's symptoms based on a 7-point scale at Week 12. A score of 1=participant felt symptoms were "very much better"; score of 2=participant felt symptoms were "much better"; score of 3=participant felt symptoms were "a little better"; score of 4=participant felt "no change" in symptoms; score of 5=participant felt symptoms were "a little worse"; score of 6=participant felt symptoms were "much worse"; score of 7=participant felt symptoms were "very much worse".
Time frame: 12 weeks
Clinician Global Impression of Improvement (CGI-I) at 12 Weeks
The CGI-I was an investigator-rated instrument that measured improvement or worsening of the participant's symptoms based on a 7-point scale. A score of 1=participant felt symptoms were "very much better"; score of 2=participant felt symptoms were "much better"; score of 3=participant felt symptoms were "a little better"; score of 4=participant felt "no change" in symptoms; score of 5=participant felt symptoms were "a little worse"; score of 6=participant felt symptoms were "much worse"; score of 7=participant felt symptoms were "very much worse".
Time frame: 12 weeks
Treatment Satisfaction Scale - Benign Prostatic Hyperplasia (TSS-BPH) at 12 Weeks: Overall
The TSS-BPH was a validated participant-rated instrument that measured participant satisfaction with treatment based on a 13-item questionnaire. The overall TSS-BPH score was converted to a percentage of the maximum value possible (percent ranged from 0-100) with lower scores indicating greater satisfaction.
Time frame: 12 weeks
Change From Baseline in International Index of Erectile Function (IIEF) Erectile Function (EF) Domain at 12 Weeks
IIEF measured self-reported EF over the past 4 weeks. Scores ranged from 0 (low or no EF)-5 (high EF) on 6 questions (1-5, 15 of the IIEF). Total EF Domain scores ranged from 1-30. Least Squares (LS) Mean of change from baseline to endpoint (Week 12 or last post-baseline value carried forward) was from an analysis of covariance (ANCOVA) and adjusted for treatment group, region, centered-baseline covariate, centered-baseline-by-treatment interaction, and treatment-by-region interaction.
Time frame: Baseline, 12 weeks
Change From Baseline in Peak Urine Flow Rate (Q-Max) at 12 Weeks
Q-max (peak urine flow rate) was measured in milliliters per second (mL/sec) using a standard calibrated flowmeter. At each visit, a uroflowmetry assessment was considered valid and data were included in the analyses only if the prevoid total bladder volume (assessed by ultrasound) was ≥150 to ≤550 mL and the voided volume (V-comp) was ≥125 mL.
Time frame: Baseline, 12 weeks
Change From Baseline in Mean Urine Flow Rate (Q-Mean) at 12 Weeks
Q-mean (mean urine flow rate) was measured in milliliters per second (mL/sec) using a standard calibrated flowmeter. At each visit, a uroflowmetry assessment was considered valid and data were included in the analyses only if the prevoid total bladder volume (assessed by ultrasound) was ≥150 to ≤550 mL and the voided volume (V-comp) was \>=125 mL.
Time frame: Baseline, 12 weeks
Change From Baseline in Volume of Voided Urine (V-Comp) at 12 Weeks
V-comp (volume of urine voided) was measured in milliliters (mL) using a standard calibrated flowmeter. At each visit, a uroflowmetry assessment was considered valid and data were included in the analyses only if the prevoid total bladder volume (assessed by ultrasound) was ≥150 to ≤550 mL and V-comp was ≥125 mL.
Time frame: Baseline, 12 weeks
Change From Baseline in Postvoid Residual Volume (PVR) at 12 Weeks
PVR was the amount of urine remaining in the bladder after void completion.
Time frame: Baseline, 12 weeks
| Milestone | Placebo | Tadalafil 5 mg | Tamsulosin 0.4 mg |
|---|---|---|---|
| Started | 172 | 171 | 168 |
| Completed | 148 | 156 | 150 |
| Not completed | 24 | 15 | 18 |
| Withdrew: Adverse event | 2 | 2 | 1 |
| Withdrew: Lack of efficacy | 3 | 0 | 0 |
| Withdrew: Lost to follow-up | 3 | 0 | 2 |
| Withdrew: Protocol violation | 8 | 5 | 8 |
| Withdrew: Withdrawal by subject | 7 | 6 | 4 |
| Withdrew: Entry criteria not met | 0 | 2 | 2 |
| Withdrew: Sponsor decision | 1 | 0 | 1 |
The IPSS Total Score was obtained by combining the scores of the responses to Component Questions 1-7. Each question was scored from 0-5 for an IPSS range of 0-35 points; higher numerical scores from the IPSS questionnaire represented greater severity of symptoms. Least Squares (LS) Mean of change from baseline to endpoint (Week 12 or last post-baseline value carried forward) was from an analysis of covariance (ANCOVA) and adjusted for treatment group, region, centered-baseline covariate, centered-baseline-by-treatment interaction, and treatment-by-region interaction.
| units on a scale | Placebo | Tadalafil 5 mg | Tamsulosin 0.4 mg |
|---|---|---|---|
| Change From Baseline in Total International Prostate Symptom Score (IPSS) at 12 Weeks | -4.2 ± 0.5 | -6.3 ± 0.5 | -5.7 ± 0.5 |
The IPSS Total Score was obtained by combining the scores of the responses to Component Questions 1-7. Each question was scored from 0-5 for an IPSS range of 0-35 points; higher numerical scores from the IPSS questionnaire represented greater severity of symptoms. Least Squares (LS) Mean of change from baseline to endpoint (Week 4 or last post-baseline value carried forward) was from an analysis of covariance (ANCOVA) and adjusted for treatment group, region, centered-baseline covariate, centered-baseline-by-treatment interaction, and treatment-by-region interaction.
| units on a scale | Placebo | Tadalafil 5 mg | Tamsulosin 0.4 mg |
|---|---|---|---|
| Change From Baseline in Total International Prostate Symptom Score (IPSS) at 4 Weeks | -3.3 ± 0.4 | -5.5 ± 0.4 | -5.7 ± 0.4 |
IPSS storage (irritative) subscore was the sum of Component Questions 2, 4 and 7 of the IPSS questionnaire. Scores ranged from 0 (no irritative symptoms) to 5 (frequent irritative symptoms); therefore, the 3 questions of the irritative subscore ranged from 0 to 15. Least Squares (LS) Mean of change from baseline to endpoint (Week 12 or last post-baseline value carried forward) was from an analysis of covariance (ANCOVA) and adjusted for treatment group, region, centered-baseline covariate, centered-baseline-by-treatment interaction, and treatment-by-region interaction.
| units on a scale | Placebo | Tadalafil 5 mg | Tamsulosin 0.4 mg |
|---|---|---|---|
| Change From Baseline in International Prostate Symptom Score (IPSS) Storage (Irritative) Subscore at 12 Weeks | -1.6 ± 0.2 | -2.2 ± 0.2 | -2.2 ± 0.2 |
IPSS voiding (obstructive) subscore was the sum of Component Questions 1, 3, 5 and 6 of the IPSS questionnaire. Scores ranged from 0 (no obstructive symptoms)-5 (frequent obstructive symptoms); therefore, the 4 questions of the obstructive score ranged from 0-20. Least Squares (LS) Mean of change from baseline to endpoint (Week 12 or last post-baseline value carried forward) was from an analysis of covariance (ANCOVA) and adjusted for treatment group, region, centered-baseline covariate, centered-baseline-by-treatment interaction, and treatment-by-region interaction.
| units on a scale | Placebo | Tadalafil 5 mg | Tamsulosin 0.4 mg |
|---|---|---|---|
| Change From Baseline in International Prostate Symptom Score (IPSS) Voiding (Obstructive) Subscore at 12 Weeks. | -2.6 ± 0.3 | -4.1 ± 0.3 | -3.5 ± 0.3 |
The IPSS nocturia question (Component Question 7) measured nocturia (need to urinate at night) over the past 4 weeks. Scores ranged from 0 (no episodes of nocturia)-5 (5 or more episodes of nocturia). Least Squares (LS) Mean of change from baseline to endpoint (Week 12 or last post-baseline value carried forward) was from an analysis of covariance (ANCOVA) and adjusted for treatment group, region, centered-baseline covariate, centered-baseline-by-treatment interaction, and treatment-by-region interaction.
| units on a scale | Placebo | Tadalafil 5 mg | Tamsulosin 0.4 mg |
|---|---|---|---|
| Change From Baseline in International Prostate Symptom Score (IPSS) Nocturia Question at 12 Weeks | -0.3 ± 0.1 | -0.5 ± 0.1 | -0.5 ± 0.1 |
IPSS QoL assessed QoL by urinary symptoms, with scores ranging from 0 (delighted)-6 (terrible). Least Squares (LS) Mean of change from baseline to endpoint (Week 12 or last post-baseline value carried forward) was from an analysis of covariance (ANCOVA) and adjusted for treatment group, region, centered-baseline covariate, centered-baseline-by-treatment interaction, and treatment-by-region interaction.
| units on a scale | Placebo | Tadalafil 5 mg | Tamsulosin 0.4 mg |
|---|---|---|---|
| Change From Baseline in International Prostate Symptom Score (IPSS) Quality of Life (QoL) Index at 12 Weeks | -1.0 ± 0.1 | -1.3 ± 0.1 | -1.1 ± 0.1 |
The mIPSS Total Score covered a time period of 1 week and was obtained by combining scores of responses to Component Questions 1-7. Each question was scored from 0-5 for an mIPSS range of 0-35 points; higher numerical scores represented greater severity of symptoms. Least Squares (LS) Mean of change from baseline to endpoint (Week 1 or last post-baseline value carried forward) was from an analysis of covariance (ANCOVA) and adjusted for treatment group, region, centered-baseline covariate, centered-baseline-by-treatment interaction, and treatment-by-region interaction.
| units on a scale | Placebo | Tadalafil 5 mg | Tamsulosin 0.4 mg |
|---|---|---|---|
| Change From Baseline in Modified International Prostate Symptom Score (mIPSS) at 1 Week | -2.5 ± 0.4 | -4.0 ± 0.4 | -4.0 ± 0.4 |
BII was a 4-item, self-administered questionnaire evaluating impact of urinary problems on overall health and activity. Total scores ranged from 0-13; higher scores represented increased perceived impact of BPH-lower urinary tract symptoms (LUTS) on overall health. Least Squares (LS) Mean of change from baseline to endpoint (Week 4 or last post-baseline value carried forward) was from an analysis of covariance (ANCOVA) and adjusted for treatment group, region, centered-baseline covariate, centered-baseline-by-treatment interaction, and treatment-by-region interaction.
| units on a scale | Placebo | Tadalafil 5 mg | Tamsulosin 0.4 mg |
|---|---|---|---|
| Change From Baseline in Benign Prostatic Hyperplasia Impact Index (BII) at 4 Weeks | -0.4 ± 0.2 | -1.2 ± 0.2 | -1.3 ± 0.2 |
BII was a 4-item, self-administered questionnaire evaluating impact of urinary problems on overall health and activity. Total scores ranged from 0-13; higher scores represented increased perceived impact of BPH-lower urinary tract symptoms (LUTS) on overall health. Least Squares (LS) Mean of change from baseline to endpoint (Week 12 or last post-baseline value carried forward) was from an analysis of covariance (ANCOVA) and adjusted for treatment group, region, centered-baseline covariate, centered-baseline-by-treatment interaction, and treatment-by-region interaction.
| units on a scale | Placebo | Tadalafil 5 mg | Tamsulosin 0.4 mg |
|---|---|---|---|
| Change From Baseline in Benign Prostatic Hyperplasia Impact Index (BII) at 12 Weeks | -0.9 ± 0.2 | -1.7 ± 0.2 | -1.5 ± 0.2 |
The PGI-I was a participant-rated instrument that measured the improvement or worsening of the participant's symptoms based on a 7-point scale at Week 12. A score of 1=participant felt symptoms were "very much better"; score of 2=participant felt symptoms were "much better"; score of 3=participant felt symptoms were "a little better"; score of 4=participant felt "no change" in symptoms; score of 5=participant felt symptoms were "a little worse"; score of 6=participant felt symptoms were "much worse"; score of 7=participant felt symptoms were "very much worse".
| participants | Placebo | Tadalafil 5 mg | Tamsulosin 0.4 mg |
|---|---|---|---|
| Very much worse | 2 | 0 | 0 |
| Much worse | 2 | 1 | 0 |
| A little worse | 4 | 6 | 8 |
| No change | 51 | 28 | 36 |
| A little better | 53 | 52 | 55 |
| Much better | 36 | 56 | 48 |
| Very much better | 11 | 17 | 10 |
The CGI-I was an investigator-rated instrument that measured improvement or worsening of the participant's symptoms based on a 7-point scale. A score of 1=participant felt symptoms were "very much better"; score of 2=participant felt symptoms were "much better"; score of 3=participant felt symptoms were "a little better"; score of 4=participant felt "no change" in symptoms; score of 5=participant felt symptoms were "a little worse"; score of 6=participant felt symptoms were "much worse"; score of 7=participant felt symptoms were "very much worse".
| participants | Placebo | Tadalafil 5 mg | Tamsulosin 0.4 mg |
|---|---|---|---|
| Very much worse | 1 | 0 | 0 |
| Much worse | 2 | 2 | 1 |
| A little worse | 6 | 5 | 7 |
| No change | 51 | 32 | 40 |
| A little better | 57 | 58 | 65 |
| Much better | 34 | 50 | 38 |
| Very much better | 9 | 16 | 6 |
The TSS-BPH was a validated participant-rated instrument that measured participant satisfaction with treatment based on a 13-item questionnaire. The overall TSS-BPH score was converted to a percentage of the maximum value possible (percent ranged from 0-100) with lower scores indicating greater satisfaction.
| units on a scale | Placebo | Tadalafil 5 mg | Tamsulosin 0.4 mg |
|---|---|---|---|
| Treatment Satisfaction Scale - Benign Prostatic Hyperplasia (TSS-BPH) at 12 Weeks: Overall | 28.9 ± 17.50 | 22.2 ± 17.74 | 28.9 ± 16.49 |
IIEF measured self-reported EF over the past 4 weeks. Scores ranged from 0 (low or no EF)-5 (high EF) on 6 questions (1-5, 15 of the IIEF). Total EF Domain scores ranged from 1-30. Least Squares (LS) Mean of change from baseline to endpoint (Week 12 or last post-baseline value carried forward) was from an analysis of covariance (ANCOVA) and adjusted for treatment group, region, centered-baseline covariate, centered-baseline-by-treatment interaction, and treatment-by-region interaction.
| units on a scale | Placebo | Tadalafil 5 mg | Tamsulosin 0.4 mg |
|---|---|---|---|
| Change From Baseline in International Index of Erectile Function (IIEF) Erectile Function (EF) Domain at 12 Weeks | 2.1 ± 0.8 | 6.0 ± 0.8 | 1.7 ± 0.8 |
Q-max (peak urine flow rate) was measured in milliliters per second (mL/sec) using a standard calibrated flowmeter. At each visit, a uroflowmetry assessment was considered valid and data were included in the analyses only if the prevoid total bladder volume (assessed by ultrasound) was ≥150 to ≤550 mL and the voided volume (V-comp) was ≥125 mL.
| milliliters per second (mL/sec) | Placebo | Tadalafil 5 mg | Tamsulosin 0.4 mg |
|---|---|---|---|
| Change From Baseline in Peak Urine Flow Rate (Q-Max) at 12 Weeks | 0.3 ± 4.84 | 1.6 ± 5.49 | 1.6 ± 4.06 |
Q-mean (mean urine flow rate) was measured in milliliters per second (mL/sec) using a standard calibrated flowmeter. At each visit, a uroflowmetry assessment was considered valid and data were included in the analyses only if the prevoid total bladder volume (assessed by ultrasound) was ≥150 to ≤550 mL and the voided volume (V-comp) was \>=125 mL.
| milliliters per second (mL/sec) | Placebo | Tadalafil 5 mg | Tamsulosin 0.4 mg |
|---|---|---|---|
| Change From Baseline in Mean Urine Flow Rate (Q-Mean) at 12 Weeks | 0.10 ± 2.72 | 1.25 ± 3.24 | 0.70 ± 3.03 |
V-comp (volume of urine voided) was measured in milliliters (mL) using a standard calibrated flowmeter. At each visit, a uroflowmetry assessment was considered valid and data were included in the analyses only if the prevoid total bladder volume (assessed by ultrasound) was ≥150 to ≤550 mL and V-comp was ≥125 mL.
| milliliter (mL) | Placebo | Tadalafil 5 mg | Tamsulosin 0.4 mg |
|---|---|---|---|
| Change From Baseline in Volume of Voided Urine (V-Comp) at 12 Weeks | 0.0 ± 110.92 | 11.0 ± 101.45 | 16.0 ± 109.30 |
PVR was the amount of urine remaining in the bladder after void completion.
| milliliter (mL) | Placebo | Tadalafil 5 mg | Tamsulosin 0.4 mg |
|---|---|---|---|
| Change From Baseline in Postvoid Residual Volume (PVR) at 12 Weeks | 0.0 ± 56.48 | -1.0 ± 46.97 | -5.5 ± 59.21 |
Non-serious events are listed at a 0% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Tadalafil 5 mg | — | 2/171 (1.2%) | 39/171 (22.8%) |
| Tamsulosin 0.4 mg | — | 2/168 (1.2%) | 40/168 (23.8%) |
| Placebo | — | 0/172 (0%) | 35/172 (20.3%) |
| Event | Tadalafil 5 mg | Tamsulosin 0.4 mg | Placebo |
|---|---|---|---|
| TachycardiaCardiac disorders | 0/171 | 1/168 | 0/172 |
| DyspepsiaGastrointestinal disorders | 0/171 | 1/168 | 0/172 |
| DizzinessNervous system disorders | 0/171 | 1/168 | 0/172 |
| HeadacheNervous system disorders | 0/171 | 1/168 | 0/172 |
| HyperhidrosisSkin and subcutaneous tissue disorders | 0/171 | 1/168 | 0/172 |
| FlushingVascular disorders | 0/171 | 1/168 | 0/172 |
| Coronary artery diseaseCardiac disorders | 1/171 | 0/168 | 0/172 |
| PancreatitisGastrointestinal disorders | 1/171 | 0/168 | 0/172 |
| Event | Tadalafil 5 mg | Tamsulosin 0.4 mg | Placebo |
|---|---|---|---|
| NasopharyngitisInfections and infestations | 5/171 | 3/168 | 8/172 |
| HeadacheNervous system disorders | 5/171 | 6/168 | 2/172 |
| DizzinessNervous system disorders | 4/171 | 5/168 | 3/172 |
| DyspepsiaGastrointestinal disorders | 4/171 | 2/168 | 0/172 |
| Back painMusculoskeletal and connective tissue disorders | 4/171 | 2/168 | 1/172 |
| CoughRespiratory, thoracic and mediastinal disorders | 2/171 | 3/168 | 1/172 |
| Gastrooesophageal reflux diseaseGastrointestinal disorders | 3/171 | 0/168 | 0/172 |
| Pain in extremityMusculoskeletal and connective tissue disorders | 3/171 | 1/168 | 0/172 |
| FlushingVascular disorders | 3/171 | 1/168 | 0/172 |
| NauseaGastrointestinal disorders | 1/171 | 1/168 | 3/172 |
| Age Continuous(years) | Placebo | Tadalafil 5 mg | Tamsulosin 0.4 mg | Total |
|---|---|---|---|---|
| Mean | 63.7 ± 8.65 | 63.5 ± 8.08 | 63.5 ± 7.76 | 63.6 ± 8.16 |
| Sex: Female, Male(Participants) | Placebo | Tadalafil 5 mg | Tamsulosin 0.4 mg | Total |
|---|---|---|---|---|
| Female | 0 | 0 | 0 | 0 |
| Male | 172 | 171 | 168 | 511 |
| Ethnicity (NIH/OMB)(Participants) | Placebo | Tadalafil 5 mg | Tamsulosin 0.4 mg | Total |
|---|---|---|---|---|
| Hispanic or Latino | 49 | 47 | 43 | 139 |
| Not Hispanic or Latino | 123 | 124 | 125 | 372 |
| Unknown or Not Reported | 0 | 0 | 0 | 0 |
| Race (NIH/OMB)(Participants) | Placebo | Tadalafil 5 mg | Tamsulosin 0.4 mg | Total |
|---|---|---|---|---|
| American Indian or Alaska Native | 41 | 40 | 37 | 118 |
| Asian | 0 | 0 | 0 | 0 |
| Native Hawaiian or Other Pacific Islander | 0 | 0 | 0 | 0 |
| Black or African American | 0 | 1 | 0 | 1 |
| White | 131 | 130 | 131 | 392 |
| More than one race | 0 | 0 | 0 | 0 |
| Unknown or Not Reported | 0 | 0 | 0 | 0 |
| Region of Enrollment(participants) | Placebo | Tadalafil 5 mg | Tamsulosin 0.4 mg | Total |
|---|---|---|---|---|
| Australia | 6 | 9 | 10 | 25 |
| Austria | 13 | 10 | 7 | 30 |
| Belgium | 5 | 6 | 7 | 18 |
| France | 9 | 9 | 12 | 30 |
| Germany | 56 | 50 | 56 | 162 |
| Greece | 8 | 4 | 7 | 19 |
| Italy | 18 | 26 | 15 | 59 |
| Mexico | 43 | 41 | 38 | 122 |
| Netherlands | 2 | 3 | 6 | 11 |
| Poland | 12 | 13 | 10 | 35 |
| Body Mass Index (BMI)(kilogram per square meter (kg/m^2)) | Placebo | Tadalafil 5 mg | Tamsulosin 0.4 mg | Total |
|---|---|---|---|---|
| Mean | 28.1 ± 4.09 | 27.1 ± 4.03 | 27.9 ± 3.73 | 27.7 ± 3.96 |
| Lower Urinary Tract Symptom (LUTS) Severity(participants) | Placebo | Tadalafil 5 mg | Tamsulosin 0.4 mg | Total |
|---|---|---|---|---|
| Moderate (IPSS <20) | 118 | 123 | 119 | 360 |
| Severe (IPSS ≥20) | 54 | 48 | 49 | 151 |
| Peak Urine Flow Rate (Qmax) Category(participants) | Placebo | Tadalafil 5 mg | Tamsulosin 0.4 mg | Total |
|---|---|---|---|---|
| <10 mL/sec | 79 | 92 | 105 | 276 |
| 10-15 mL/sec | 69 | 63 | 53 | 185 |
| >15 mL/sec | 18 | 12 | 7 | 37 |
7 further baseline measures are reported on the registry.
The record gives a start of Oct 2009, a primary completion of Jan 2011 and a completion of Jan 2011. It does not say whether these dates are actual or estimated.
Results were first posted in Dec 2011, 11 months after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Mar 2012. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Tadalafil